Invasive Mucormycosis

• FDA approval · 2025-03-24
  FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)

  The FDA approved a supplemental application for Cresemba (isavuconazonium sulfate) from Astellas Pharma US, Inc.

• FDA approval · 2023-12-08
  FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)

  FDA approved a supplemental application for Cresemba (isavuconazonium sulfate) from Astellas Pharma US, Inc.

• FDA approval · 2023-12-08
  FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)

  FDA approved a supplemental application for CRESEMBA (isavuconazonium sulfate) submitted by Astellas Pharma US, Inc. The approval updates th…

• CLINICAL_TRIALS trial_result · 2023-09-21
  Clinical Trial Update: A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants [Phase 2]

  This update reports the results of a Phase 2 pediatric study evaluating isavuconazonium sulfate for invasive aspergillosis and invasive muco…

• FDA approval · 2021-02-01
  FDA Approved: POSACONAZOLE — Original Application (Lupin Pharmaceuticals, Inc.)

  FDA approved the original application for posaconazole from Lupin Pharmaceuticals, enabling generic availability of the antifungal.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2015-03-06
  FDA Approved: CRESEMBA — Original Application (Astellas Pharma US, Inc.)

  FDA approved CRESEMBA (isavuconazonium sulfate) from Astellas Pharma US, Inc. as an antifungal treatment. The approval covers invasive asper…